What Is Vildagliptin Powder？

describe:

Vildagliptin (LAF-237; NVP-LAF 237) inhibits DPP-4 with IC50 of 2.3 nM. IC50 value: 2.3 nM[1] Target: DPP-4 In vitro: Vildagliptin is an N-substituted glycyl-2-cyanopyrrolidine (Figure 2). It is a potent, competitive and reversible inhibitor of DPP-4 in vitro and in rodents with a median inhibitory concentration (IC50) of ~2-3 nmol/L. Importantly, vildagliptin inhibits DPP-4 with high specificity compared to other similar peptidases with IC50s over 200 mol/L .

Basic Attributes

• CAS No：274901-16-5

• Molecular Formula ：C17H25N3O2

• Molecular Mass ：303.39900

• Exact Mass ：303.19500

• PSA ：76.36000

• LogP ：1.50308

Characteristics

• Appearance ：white crystalline powder

• Density ：1.27 g/cm3

• Melting Point ：153-155°C

• Bolling Point ：531.3ºC at 760 mmHg

• Flash Point ：275.1ºC

Safety Information

• HS Code ：2933990090

• Safety Instructions ：24/25-26-28-36/37/39

Usage

Vildagliptin (previously LAF237, trade names Galvus, Zomelis,) is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus.

China Vildagliptin Export Data

Data referenced from General Administration of Customs,P.R.China

                               2018.11-2019.11 China Vildagliptin Export Data